Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease.
|Title:||Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease.||Authors:||Griffin, Matthew
Barry, Frank P.
|Permanent link:||http://hdl.handle.net/10197/5004||Date:||14-Mar-2010||Abstract:||Adult mesenchymal stem cells (MSCs) are non-hematopoietic cells with multi-lineage potential to differentiate into various tissues of mesodermal origin. They can be isolated from bone marrow and other tissues and have the capacity to extensively proliferate in vitro. Moreover, MSCs have also been shown to produce anti-inflammatory molecules which can modulate humoral and cellular immune responses. Considering their regenerative potential and immunoregulatory effect, MSC therapy is a promising tool in the treatment of degenerative, inflammatory, and autoimmune diseases. However, the current understanding from results of clinical trials is that MSC-therapy is safe but its therapeutic efficiency needs to be improved. In this article we will focus on options for genetic manipulation of MSCs and on current progress in adapting genetically-modified MSCs for clinical use in acute cardiovascular disease.||Type of material:||Journal Article||Publisher:||Discovery Medicine||Copyright (published version):||2010 Discovery Medicine||Keywords:||Medical Specialties;Life Sciences;Species and Cell Types;Research Technology;Therapeutic Technology and Methodology;Pharmaceutical and Healthcare Indusrty||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||SBI Research Collection|
Show full item record
Page view(s) 5040
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.